A Phase I/II Optimal Dose Study of Lenalidomide in the Non-5q- LOW and INT-1 Risk MDS [myelodysplastic syndrome] Patients.
Phase of Trial: Phase I/II
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Lenalidomide (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 09 Aug 2012 Planned end date changed from 1 Jul 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 04 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 04 Jan 2012 Actual patient number is 8 according to ClinicalTrials.gov.